.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ02_Liraglutide.Liraglutide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ02_Liraglutide.Liraglutide| name: | Liraglutide |
| ATC code: | A10BJ02 | route: | subcutaneous |
| n-compartments | 1 |
Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used primarily for the treatment of type 2 diabetes mellitus and as an anti-obesity agent. It is approved for use in adults and pediatric patients for glycemic control and for chronic weight management.
Pharmacokinetic parameters determined in adult healthy subjects and patients with type 2 diabetes following subcutaneous administration.
Watson, E, et al., & Ingwersen, SH (2010). Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. Journal of clinical pharmacology 50(8) 886–894. DOI:10.1177/0091270009354996 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20133507
Mastrandrea, LD, et al., & Riesenberg, RA (2019). Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Pediatric obesity 14(5) e12495–None. DOI:10.1111/ijpo.12495 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30653847
Danne, T, et al., & Kordonouri, O (2017). Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years. The Journal of pediatrics 181 146–153.e3. DOI:10.1016/j.jpeds.2016.10.076 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27979579